Jos P.M. Bökkerink - Concepedia

Author

Jos P.M. Bökkerink

Also Known As

Jos Bokkerink, Jos Bökkerink, Jos P Bokkerink, Jos P Bökkerink, Jos P M Bökkerink, Jos P. Bökkerink, Jos P. M. Bokkerink, Jos P. M. Bökkerink, Jos P.M. Bokkerink, Jos P.M. Bökkerink

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center Stichting Kinderoncologie Nederland Amsterdam UMC Location Vrije Universiteit Amsterdam Wilhelmina Children's Hospital

About

Jos P.M. Bökkerink is an author at Radboud University Nijmegen specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	840
2	Health Sciences	2	2	303
3	Biochemistry	2	2	46
4	Natural Sciences	1	1	23
5	Public Health	1	1	62

Jos P.M. Bökkerink

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Allelic Loss of Chromosome 1p as a Predictor of Unfavorable Outcome in Patients with Neuroblastoma Huib N. Caron, Peter van Sluis, Jan de Kraker, New England Journal of Medicine	1996	427
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004) A. Veerman, Willem A. Kamps, Henk van den Berg, The Lancet Oncology Hematological MalignancyProtocol All-9Lymphoid NeoplasiaOncologyHematology	2009	247
Prospective Study on Incidence, Risk Factors, and Long-Term Outcome of Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia M.L. te Winkel, Rob Pieters, Wim C.J. Hop, Journal of Clinical Oncology	2011	161
Treatment of Children and Adolescents With Hodgkin Lymphoma Without Radiotherapy for Patients in Complete Remission After Chemotherapy: Final Results of the Multinational Trial GPOH-HD95 W Dörffel, U Rühl, H Lüders, Journal of Clinical Oncology	2013	141
Salvage Therapy of Progressive and Recurrent Hodgkin’s Disease: Results From a Multicenter Study of the Pediatric DAL/GPOH-HD Study Group G. Schellong, W Dörffel, Alexander Claviez, Journal of Clinical Oncology	2005	127
6-Mercaptopurine: Cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts Jos P.M. Bökkerink, E. H. Stet, Ronney A. De Abreu, Biochemical Pharmacology Lymphoid NeoplasiaBiochemical PharmacologyImmunologyAnti-cancer AgentAdult T-cell Leukemia-lymphoma	1993	98
Abnormal NT‐pro‐BNP levels in asymptomatic long‐term survivors of childhood cancer treated with anthracyclines Annelies M. C. Mavinkurve‐Groothuis, Jacqueline J. Loonen, Louise Bellersen, Pediatric Blood & Cancer	2009	84
The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts Mario H.J. Vogt, E. H. Stet, Ronney A. De Abreu, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Lymphoid NeoplasiaMethylmercaptopurine RibonucleosideOncologyMedicineImmunology	1993	69
Myocardial Strain and Strain Rate in Monitoring Subclinical Heart Failure in Asymptomatic Long-Term Survivors of Childhood Cancer Annelies M. C. Mavinkurve‐Groothuis, Jacqueline J. Loonen, Karen A. Marcus, Ultrasound in Medicine & Biology CardiomyopathyHeart FailureCardiovascular DiseaseCardiac MechanicMedicine	2010	62
Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages Jos P.M. Bökkerink, Marinka A.H. Bakker, Tilly W. Hulscher, Biochemical Pharmacology Lymphoid NeoplasiaRadiation OncologyMalignant DiseaseMedicineDifferent Lineages	1988	56

Page 1